Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials • Medical Devices & Mechanical Engineering
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready
Novaflux Inc. currently manages 4 pending office actions within the Chemistry & Materials technology area. This portfolio is distributed across 4 distinct art units, which indicates that the filings are reviewed by 4 separate technical groups at the patent office. The involvement of 4 distinct examiners suggests that the prosecution strategy is not concentrated under a single individual, which may lead to varying examination styles across the pending matters.
FREHE, WILLIAM R is identified as the busiest examiner for this portfolio, currently handling 1 pending office action. Because this busiest examiner manages 1 of the 4 total pending actions, the workload is spread across the examination corps. Practitioners should prepare for a prosecution experience where no single examiner's precedents will dominate the portfolio's outcomes. The presence of 4 examiners for 4 pending actions reflects a prosecution landscape where counsel must monitor 4 separate sets of examiner behaviors and art unit trends simultaneously.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (50%) |
| Double-patenting only | 1 (25%) |
| Multi-statute (no §101) | 1 (25%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| FREHE, WILLIAM R | 1 | 59.7% | +42.2% |
| MRUK, BRIAN P | 1 | 74.2% | +28.1% |
| CRAIGO, WILLIAM A | 1 | 48.9% | +38.1% |
| MENON, KRISHNAN S | 1 | 59.7% | +11.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17339116 | Hollow fibers for outside-in-dialysis applications | MENON, KRISHNAN S | 77d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17339116 | Hollow fibers for outside-in-dialysis applications | MENON, KRISHNAN S | 77d overdue |
| 18198755 | Drug-releasing catheter extender-lengthener and catheter extension tube | FREHE, WILLIAM R | — |
| 18142248 | COMPOSITIONS FOR CLEANING AND DECONTAMINATION | MRUK, BRIAN P | — |
| 17986604 | DRUG-RELEASING POLYMER COMPOSITION AND DEVICE | CRAIGO, WILLIAM A | — |
| Art Unit | Apps |
|---|---|
| 3783 | 1 |
| 1761 | 1 |
| 1615 | 1 |
| 1777 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18198755 | Drug-releasing catheter extender-lengthener and catheter extension tube | FREHE, WILLIAM R | 3783 | §103 | Non-Final OA | — | Pending | May 17, 2023 |
| 18142248 | COMPOSITIONS FOR CLEANING AND DECONTAMINATION | MRUK, BRIAN P | 1761 | DP | Non-Final OA | — | Pending | May 02, 2023 |
| 17986604 | DRUG-RELEASING POLYMER COMPOSITION AND DEVICE | CRAIGO, WILLIAM A | 1615 | §103 | Final Rejection | — | Pending | Nov 14, 2022 |
| 17339116 | Hollow fibers for outside-in-dialysis applications | MENON, KRISHNAN S | 1777 | §103§112 | Final Rejection | 77d overdue | Pending | Jun 04, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNovaflux Inc. has 4 pending office actions as of October 2026, spread across 4 art units and 4 examiners.
William R Frehe has the most, with 1 of Novaflux Inc.'s pending office actions.
Mostly Chemistry & Materials (USPTO Tech Center 1700), based on where its pending office actions are examined.
